hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml pre-filled syringe
csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.
hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml pre-filled syringe
csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.
hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml vial
csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.
hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml vial
csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.
hizentra human normal immunoglobulin 20% solution for subcutaneous injection 50 ml vial
csl behring australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.
hizentra human normal immunoglobulin 20% solution for subcutaneous injection 20 ml vial
csl behring australia pty ltd - normal immunoglobulin, quantity: 4 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.
water for injections water for injections 20 ml ampoule
interpharma pty ltd - water for injections -
water for injections water for injections 5 ml ampoule
interpharma pty ltd - water for injections -
carimune nanofiltered- human immunoglobulin g injection, powder, lyophilized, for solution
csl behring ag - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - human immunoglobulin g 6 g - carimune® nf is indicated for the maintenance treatment of patients with primary immunodeficiencies (pid), e.g., common variable immunodeficiency, x-linked agammaglobulinemia, severe combined immunodeficiency.30,32-34 carimune® nf is preferable to intramuscular immune globulin (human) preparations in treating patients who require an immediate and large increase in the intravascular immunoglobulin level28 , in patients with limited muscle mass, and in patients with bleeding tendencies for whom intramuscular injections are contraindicated. the infusions must be repeated at regular intervals. please see dosage and administration section. a controlled study was performed in children in which carimune® was compared with steroids for the treatment of acute (defined as less than 6 months duration) itp. in this study sequential platelet levels of 30,000, 100,000, and 150,000/µl were all achieved faster with carimune® than with steroids and without any of the side effects associated with steroids.29,35 howeve
veterinary sterile water- sterile water injection
vedco, inc. - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - water 100 g in 100 ml - veterinary sterile water for injection is suitable for use as a diluent for the preparation of pharmaceutical solutions none known